EMA to scour medical literature for potential safety concerns from popular drugs
This article was originally published in SRA
Executive Summary
The European Medicines Agency is preparing to launch a new service under which it would monitor medical literature for reports of suspected adverse reactions from drugs containing certain active substances, and then submit the relevant case reports into the EudraVigilance system on behalf of drug companies.
You may also be interested in...
Roadmap On Improvements To EMA's Literature Monitoring Service Due By Year End
The European Medicines Agency will be looking for quick wins as well as long-term improvements when it revises its medical literature monitoring service. It will soon publish a roadmap for improving the service with details of when the changes might occur.
EMA Tackles Complexities Introduced By Literature Monitoring Service
The European Medicines Agency is looking at ways to improve and simplify its medical literature monitoring service, which has created new complexities for the generics pharmaceutical industry.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.